Avalo Therapeutics AVTX Cash Flow Statement (2014-2026)

NASDAQ AVTX
$19.23 +0.23 (+1.21%)
At close: Sep 4, 2026 · 4:00 PM EDT
Reported Financials

Avalo Therapeutics Quarterly Cash Flow Statement

Periods 48 quarters
Latest Jun 2026

Avalo Therapeutics reported cash from operations of -$20.00M and free cash flow of -$20.00M for the quarter ended Jun 2026, down 75.6% year over year. This cash flow statement covers 48 quarters of results from Sep 2014 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-17.39M-19.22M-22.05M-12.99M3.19M-9.81M-9.96M-8.19M-5.23M-8.17M-121.29M98.46M23.04M-35.34M-13.15M-20.77M-30.62M-13.72M-19.63M-36.36M
Share-based Compensation
1.76M1.89M5.31M0.67M0.73M0.84M0.85M0.89M0.95M0.78M0.63M0.47M1.85M2.90M3.24M2.72M3.15M4.51M3.58M5.30M
Deferred Taxes
0.01M-0.06M0.01M0.01M0.01M0.01M0.01M0.01M0.01M-0.01M0.01M0.01M-0.01M0.11M0.01M0.02M0.01M0.13M0.01M0.02M
Gains from Investment Securities
1,700.00M79.28M-112.05M-36.02M26.46M6.57M
Asset Writedowns and Impairment
Cash from Operations
-16.29M-17.10M-16.07M-12.47M5.73M-3.94M-10.05M-11.03M-6.84M-2.77M-6.20M-16.28M-11.53M-15.04M-9.46M-11.39M-16.36M-14.29M-17.70M-20.00M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
0.34M0.35M0.35M0.34M0.35M0.35M0.35M0.35M0.90M0.15M0.35M0.20M0.11M0.42M
Depreciation & Amortization (CF)Depreciation & Amortization
0.46M0.29M0.07M0.03M0.03M0.04M0.03M0.04M0.04M0.04M0.03M0.03M0.03M0.07M0.14M0.13M0.06M0.02M0.02M0.02M
Change in Working Capital
Change in Receivables
-2.69M-0.38M-0.12M-0.39M-0.54M0.04M-0.04M
Change in Inventory
-0.00M0.02M-0.01M-0.00M-0.00M-0.00M-0.00M-0.00M-0.02M
Change in Account Payables
1.32M-0.20M0.39M-1.59M-0.72M1.44M2.68M-4.81M0.04M-0.34M0.47M-0.26M1.16M-1.53M0.40M1.69M-1.89M-0.34M0.22M2.99M
Change in Accured Expenses
-2.31M0.65M-2.29M-1.25M0.39M-0.49M-4.94M-0.69M-2.46M-0.96M-1.65M0.40M-0.86M1.00M-1.70M1.99M1.02M5.35M-1.50M6.62M
Change in Taxes
Other Working Capital Changes
-0.34M0.96M0.31M-0.80M-0.77M0.17M0.34M-0.49M-0.20M-0.10M0.05M1.44M1.78M-0.40M-2.49M0.07M0.24M4.77M-0.23M0.92M
Investing Activities
Capital Expenditures
1.98M-1.00M0.06M0.04M0.16M
Sales of Property, Plant and Equipment
0.03M
Acquisitions
0.36M
Divestments
Change in Acquisitions & Divestments
10.50M21.50M25.50M23.88M
Cash from Investing Activities
-0.08M-0.01M-0.06M-0.04M-0.13M0.36M-70.86M-13.26M2.40M25.50M-329.93M
Financing Activities
Other financing activities
0.16M0.05M0.07M108.10M7.53M142.70M0.04M0.73M2.18M5.23M
Debt Issuance and Repayment
Long-Term Debt Issuances
15.00M-14.81M6.00M
Long-Term Debt Repayments
Change in Capital Stock
Net Shares Issued and Repurchased
Net Equity Issued and Repurchased
25.94M
Misc.
Cash from Financing Activities
47.64M0.08M-14.78M0.08M13.75M0.60M10.70M0.00M108.61M-0.47M67.71M-0.47M14.37M0.69M1.40M410.21M
Change in Cash
31.27M-17.03M-16.07M-27.31M5.69M-3.86M3.56M-10.43M3.86M-2.77M102.77M-16.75M-11.53M52.66M-9.46M-82.72M-15.26M-11.16M9.21M60.30M
Free Cash Flow
-18.27M-16.10M-16.07M-12.53M5.69M-3.94M-10.21M-11.03M-6.84M-2.77M-6.20M-16.28M-11.53M-15.04M-9.46M-11.39M-16.36M-14.29M-17.70M-20.00M
Net Cash Flow
31.27M-17.03M-16.07M-27.31M5.69M-3.86M3.56M-10.43M3.86M-2.77M102.77M-16.75M-11.53M52.66M-9.46M-82.72M-15.26M-11.20M9.20M60.28M